TSHA vs. EDIT, CCCC, ADPT, VYGR, ITOS, LXEO, FATE, ALVO, ALLO, and REPL
Should you be buying Taysha Gene Therapies stock or one of its competitors? The main competitors of Taysha Gene Therapies include Editas Medicine (EDIT), C4 Therapeutics (CCCC), Adaptive Biotechnologies (ADPT), Voyager Therapeutics (VYGR), iTeos Therapeutics (ITOS), Lexeo Therapeutics (LXEO), Fate Therapeutics (FATE), Alvotech (ALVO), Allogene Therapeutics (ALLO), and Replimune Group (REPL). These companies are all part of the "biological products, except diagnostic" industry.
Editas Medicine (NASDAQ:EDIT) and Taysha Gene Therapies (NASDAQ:TSHA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, community ranking, profitability, earnings, institutional ownership, analyst recommendations, valuation, dividends and media sentiment.
71.9% of Editas Medicine shares are held by institutional investors. Comparatively, 77.7% of Taysha Gene Therapies shares are held by institutional investors. 1.9% of Editas Medicine shares are held by insiders. Comparatively, 2.7% of Taysha Gene Therapies shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Taysha Gene Therapies has lower revenue, but higher earnings than Editas Medicine. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.
Editas Medicine currently has a consensus price target of $13.90, suggesting a potential upside of 135.99%. Taysha Gene Therapies has a consensus price target of $7.00, suggesting a potential upside of 122.93%. Given Taysha Gene Therapies' higher probable upside, equities analysts plainly believe Editas Medicine is more favorable than Taysha Gene Therapies.
In the previous week, Editas Medicine had 3 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 24 mentions for Editas Medicine and 21 mentions for Taysha Gene Therapies. Taysha Gene Therapies' average media sentiment score of 0.52 beat Editas Medicine's score of 0.49 indicating that Editas Medicine is being referred to more favorably in the media.
Editas Medicine has a beta of 2.09, meaning that its stock price is 109% more volatile than the S&P 500. Comparatively, Taysha Gene Therapies has a beta of 0.37, meaning that its stock price is 63% less volatile than the S&P 500.
Editas Medicine has a net margin of -239.36% compared to Editas Medicine's net margin of -722.06%. Editas Medicine's return on equity of 0.00% beat Taysha Gene Therapies' return on equity.
Editas Medicine received 214 more outperform votes than Taysha Gene Therapies when rated by MarketBeat users. However, 73.95% of users gave Taysha Gene Therapies an outperform vote while only 53.83% of users gave Editas Medicine an outperform vote.
Summary
Editas Medicine and Taysha Gene Therapies tied by winning 9 of the 18 factors compared between the two stocks.
Get Taysha Gene Therapies News Delivered to You Automatically
Sign up to receive the latest news and ratings for TSHA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TSHA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Taysha Gene Therapies Competitors List
Related Companies and Tools
